Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that
is expressed in the majority of anaplastic large-cell lymphomas. ALK is a receptor protein …

Abstract Concepts and experimental models derived from basic research have been
successfully applied to the field of molecular oncology, tremendously increasing our …

Lung cancer has long been recognized as an extremely heterogeneous disease, since its
development is unique in every patient in terms of clinical characterizations, prognosis …

The onset of a new histology is a resistant mechanism to tyrosine kinase inhibitors (TKI) in
lung adenocarcinoma (ADK), but this phenomenon has not yet been fully clarified. We …

Although clinical trials of molecular therapies targeting critical biomarkers (mTOR, epidermal
growth factor receptor/epidermal growth factor receptor 2, and vascular endothelial growth …

The transcriptional factor SALL4, an important stem cell regulator, is expressed in
hematopoietic stem cells and various malignancies, but its role in EGFR-mutated NSCLCs …

Tumour drug resistance is a major issue in the management of lung cancer patients as
almost all lung tumours are either intrinsically resistant or quickly develop acquired …

Introduction Patients with non–small-cell lung cancer (NSCLC) with somatic activating
mutations of the epidermal growth factor receptor gene (EGFR mutations) generally respond …

Simple Summary Effective cancer treatment hinges upon overcoming therapeutic resistance
mechanisms that allow for the continued proliferation of cancer cell subpopulations …

Lung cancer is one of the most lethal types of cancer, and its poor prognosis is primarily due
to drug resistance and cancer recurrence. As it is associated with a low five‑year survival …